formally evaluate the validity of the screens with regards to their ability to correctly identify ADEs. Validity was expressed as positive predictive value (PPV). RESULTS: Ten studies published between 1992 and 2000 met the inclusion criteria. Three approaches used to measure ADE incidence were identified. Two studies screened for generic adverse outcomes (e.g., inpatient deaths), the average PPVs were 1% and 17.4%. Five studies exclusively screened for surrogate outcomes (antidotes commonly used to treat ADEs, or critical lab values, such as elevated creatinine or drug levels) to predict the occurrence of an ADE, with PPVs of 9, 12, 13, 18 and 37%. Three studies tested screens that combined medications and intermediate outcomes (PPVs 12.4, 45 and 53%) . CONCLUSIONS: Automated health care data screens show promise as ADE incidence measure. Their current validity, however, does not appear to be sufficient for cross-sectional comparisons or the evaluation of quality improvement initiatives. Increasing sophistication of the screens by including multiple variables that link process components (e.g. medication) along with adverse outcomes or surrogates (e.g. lab values, antidotes) appear to increase screen validity. 
MENTAL HEALTH (including

OBJECTIVE:
Effectiveness trials are designed to evaluate patients in their natural setting with fewer constraints than in efficacy trials. The less-structured environment can result in a failed trial if participant activity is unknown. We prepared for this possibility by including electronic monitoring of medication dosing in a multicenter trial.
METHODS:
The trial was designed to assess the effectiveness of naltrexone for the treatment of chronic alcoholism. Patients took either naltrexone or placebo once daily, using MEMS caps (APREX, Union City, CA) on their medication bottles to record the date and time of each opening. We planned analyses by intentionto-treat and covarying compliance as continuous and categorical variables (grouped as taking medication during 0-24%, 25-49%, 50-74%, >75% of weeks). RESULTS: Primary endpoints showed no differences between treatment groups at 3 months. Electronic monitoring revealed that patients took 72 + 31% of naltrexone and 70 + 31% of placebo doses (overall compliance rates). Naltrexone was taken by 13%, 11%, 12%, and 65% of patients by category. Placebo was taken by 14%, 14%, 11%, and 61% of patients by category. Compliance rates were not significantly different overall or by category between treatment groups. Planned secondary analyses demonstrated that compliance was a predictor of success (p = 0.03 for drinks/day), with no interaction for treatment.
CONCLUSION: These data demonstrate the value of electronic compliance measurement that provided data on any period needed for analyses. Without these data, the results of a complex and expensive study would have been questioned. Critics could have charged that compliance rates differed among treatment groups, or that inadequate amounts of medication were taken to assess outcomes. 
PMH2
ESTABLISHING THE EXPECTED RATE OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE
METHODS:
Data from a Canadian cohort study of 206 patients with an initial SMMSE between 10 and 24 were used to find determinants of the three year probability of reaching a highly dependent stage, defined as SMMSE <10. The regression equations were also used to derive a reference failure-time curve. The predicted progression was compared with that observed in a US study (N = 597). RESULTS: Proportional hazards analyses showed that at the mild stage (SMMSE 19 to 24) the presence of hallucinations was associated with a more rapid decline, whereas at the moderate stage (SMMSE 10 to 18) the important predictors of decline were a lower baseline SMMSE score and longer time since onset. Absence of hallucinations in patients with an SMMSE above 18, implied a 79% probability of remaining independent after three years; presence of hallucinations reduced this to 52%, while a prior rate of decline of 2 points/year did so even further to 43%. Less than half of patients whose SMMSE was already below 19 and who had symptoms for five years or longer remained independent after three years. An initial score below 14 resulted in a probability below 30%. The predictions based on the Canadian study showed reasonable agreement with the progression observed in the US study. CONCLUSIONS: These equations permit estimation of the expected progression of Alzheimer's disease, and will aid clinicians when advising patients and their caregivers about prognosis and treatment. 
PMH3
ANTIPSYCHOTIC AGENTS AND THE RISK OF DEVELOPING DIABETES
OBJECTIVES:
To assess the risk of diabetes among patients undergoing treatment with risperidone vs. haloperidol. A series of case reports had associated some antipsychotic agents with diabetes. METHODS: Patients with at least one prescription for either haloperidol or risperidone between January 1997 and 31st December 1999 recorded in the Regie de l'Assurance Maladie de Quebec database, excluding those dispensed clozapine or olanzapine during the study period or diagnosed with diabetes (defined as either a recorded ICD9 250.0 to 250.93 or a prescription for insulin or an oral hypoglycemic agent) before beginning anti-psychotic therapy, were divided into haloperidol recipients (N = 14,602) and those receiving risperidone but not haloperidol (N = 9,961). New diabetes diagnoses after the first antipsychotic prescription were tabulated; censoring at study end or the last service date if there was no record of using any services during the last six months of follow-up. Crude hazard ratios and proportional hazards analyses were carried out. RESULTS: 406 patients developed diabetes after being prescribed haloperidol, and 123 after risperidone, a crude hazard ratio of 2.29 (95% CI 1.81-2.90). When correcting for imbalances in age, and gender, using proportional hazards analysis, haloperidol still increased the risk of diabetes by 93% (HR = 1.93, 95% CI 1.57-2.37, P < 0.0001). Correction for other imbalances did not change the findings. CONCLUSIONS: Haloperidol was associated with an increased risk of developing diabetes compared to risperidone. Additional studies are required to identify a biological basis for this association, and to examine other atypical antipsychotics to determine which have the lowest risk of diabetes. 
PMH4
SUPPLEMENTAL ANALYSIS OF THE QUETIAPINE EXPERIENCE WITH SAFETY AND TOLERABILITY (QUEST) STUDY
OBJECTIVE:
To assess whether a 5-factor instead of 3-factor model more completely describes the range of psychotic symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) with data from the Quetiapine Experience with Safety and Tolerability (QUEST) trial, and to reevaluate the comparative efficacy of quetiapine and risperidone using the 5-symptom model.
METHODS:
We used exploratory factor analysis (EFA) to test whether three factors adequately describe symptoms as measured by the PANSS or if more factors are needed. The initial EFA is carried out using only baseline data. Evaluating the test for breaks in eigen values determines the number of factors. We used the n-factor rule to retain and rotate enough factors to explain 99% of the variation. Using the derived factorial structure, we performed comparative analyses on the intent-to-treat (ITT) population and on patients with clinically significant baseline symptoms (CSBS) at 2 and 4 months. RESULTS: 554 patients had completed PANSS data; 5 factors explained 99.9% of data variance and labeled negative, positive, activation, dysphoria, and autistic preoccupation symptoms with corresponding eigen values 28.97, 7.55, 3.59, 2.63 and 1.45 explaining 66%, 17%, 8%, 6%, and 3% of the variation. Statistical analyses found that, compared with risperidone, quetiapine consistently improves dysphoria sooner and in patients with CSBS. At 2 months quetiapine-treated patients' absolute change from baseline was -3.11 compared to -2.22 (P = 0.03). For patients with clinically significant baseline negative symptoms, at 2-months the comparative change in dsyphoria was -3.79 vs. -2.34 (P = 0.02). In patients with clinically significant positive symptoms, quetiapine improved dsyphoria symptoms better than risperidone at 2 and 4-months, -4.06 vs. -2.24 (P = 0.01) and -4.73 vs. -2.88 (P = 0.03). CONCLUSIONS: PANSS is more completely described with five symptoms. Compared with risperidone, quetiapine displays clinical advantage in improving dysphoria not evident when a 3-factor model is used. 
PMH5
EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE
OBJECTIVES:
Because clinical outcomes depression treatment in primary care settings tend to be poor, we developed and evaluated the efficacy of two augmentations to antidepressant treatment to be delivered by primary care nurses. METHODS: We conducted a randomized trial comparing usual care, telehealth care, and telehealth care plus peer support for depressed patients seen in primary care in an HMO setting. Assessments were conducted at baseline, 6 weeks and 6 months after study enrollment at two managed care adult primary care clinics. Participants were 303 patients recently started on antidepressants. The intervention consisted of: telehealth care; emotional
